Medtronic’s novel PulseSelect Pulsed Field Ablation System to treat atrial fibrillation is first PFA to receive FDA approval
Medtronic has received US FDA approval for the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the European CE Mark approval for the PulseSelect PFA system in November.